Like this complaint, these Risperdal lawsuits also claim that the drug was aggressively marketed for off-label pediatric indications.
New York, New York (PRWEB) February 13, 2015
The Risperdal lawyers (http://www.risperdallawsuit2014.com/) at Bernstein Liebhard LLP note the filing of a new lawsuit that alleges a Texas man developed gynecomastia due to his use of the atypical antipsychotic medication as a boy. According to a February 11th report from the Southeast Texas Record, the Plaintiff was prescribed Risperdal off-label to treat ADHD when he was 7-years-old.* The lawsuit, which is currently pending in Texas’s Jefferson County District Court, accuses the manufacturers of Risperdal of rigorously marketing the medication for use in children, even though it had not yet been approved for any pediatric indications. (Case No. A-196444)
“Our Firm is currently representing numerous plaintiffs who are also alleged to have experienced male breast growth due to their use of Risperdal. Like this complaint, these Risperdal lawsuits also claim that the drug was aggressively marketed for off-label pediatric indications,” says Bernstein Liebhard LLP, a nationwide law firm representing the victims of defective drugs and medical devices. The Firm is currently offering free legal consultations to men and boys who allegedly developed gynecomastia, or male breast growth, due to their use of Risperdal.
Risperdal is an atypical antipsychotic drug that is approved by the U.S. Food & Drug Administration (FDA) to treat adult and adolescent schizophrenia, bipolar disorder in adults and children ages 10-to-17, and irritability in children (5-to-16 years of age) with autistic disorder. However, recent research suggests that Risperdal is also prescribed for children with ADHD, although it has not been specifically cleared for this use by regulators.**
The Texas lawsuit is only one of hundreds currently pending in U.S. courts that claim Risperdal caused patients to experience gynecomastia and other serious complications. According to court documents, nearly 1,300 Risperdal lawsuits have been filed in a mass tort litigation underway in Pennsylvania’s Philadelphia Court of Common Pleas, where Bernstein Liebhard LLP is actively filing claims. (In Re: Risperdal Litigation, Case Number 100300296).
Court records indicate that a bellwether trial involving a gynecomastia case is currently underway in the Pennsylvania proceeding. According to Bernstein Liebhard LLP, the outcome of the proceeding could provide important insight into how juries might rule in similar cases involving allegations of male breast growth. Like the case now pending in Texas, the lawsuit at trial was filed on behalf of a man who was allegedly prescribed Risperdal as a child for an off-label use. The complaint also alleges that Johnson & Johnson and its Janssen Pharmaceuticals unit improperly promoted Risperdal for unapproved pediatric indications before any such uses were cleared by federal regulators in 2006. (Case No. 1204-01997)
According to Bernstein Liebhard LLP, these lawsuits are not the only time Johnson & Johnson and Janssen have faced scrutiny over their marketing of Risperdal. In November 2013, the companies agreed to pay $2.2 billion to resolve criminal and civil charges levied by the U.S. Department of Justice regarding the marketing of several medications, including Risperdal. Among other things, the drug makers were accused of improperly promoting the antipsychotic medication for unapproved uses, and of paying kickbacks to physicians who prescribed Risperdal. According to the Department of Justice, the settlement ranked among the largest involving healthcare fraud in U.S. history. (U.S. District Court, Eastern District of Pennsylvania, 04-cv-1529)
Victims of gynecomastia allegedly related to the use of Risperdal may be able to recover compensation for medical bills, lost wages, pain and suffering and other damages. To learn more about filing a Risperdal lawsuit, please visit Bernstein Liebhard LLP’s website. For a free case review, please call 800-511-5092.
*setexasrecord.com/news/301656-man-blames-risperdal-injuries, Southeast Texas Record, February 11, 2015
**health.usnews.com/health-news/news/articles/2012/08/07/more-kids-taking-antipsychotics-for-adhd-study, U.S. News & World Report, August 7, 2012
About Bernstein Liebhard LLP
Bernstein Liebhard LLP is a New York-based law firm exclusively representing injured persons in complex individual and class action lawsuits nationwide since 1993. As a national law firm, Bernstein Liebhard LLP possesses all of the legal and financial resources required to successfully challenge billion dollar pharmaceutical and medical device companies. As a result, our attorneys and legal staff have been able to recover more than $3 billion on behalf of our clients. The Firm has been named by The National Law Journal to the Plaintiffs’ Hot List, recognizing the top plaintiffs firms in the country, for the past 12 consecutive years. Bernstein Liebhard LLP is the only firm in the country to be named to this prestigious list every year since it was first published in 2003.
Bernstein Liebhard LLP
10 East 40th Street
New York, New York 10016
ATTORNEY ADVERTISING. © 2015 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, 800-511-5092. Prior results do not guarantee or predict a similar outcome with respect to any future matter.
Felecia L. Stern, Esq.
info (at) consumerinjurylawyers (dot) com